How governments assess the cost-benefit of R&D
The Green Book is the UK government’s guide for civil servants and policymakers on the appraisal of projects – that is, the assessment of the costs, benefits and risks associated with different courses of action, to inform the government’s policy and investment decisions.
There are various supplements to the Green Book, recognising the specificity of appraising projects in different areas: transport, health, climate, and others. At the October Budget this year, the Treasury launched guidance on developing “place-based” business cases: coordinated investment programmes for an area covering multiple disparate projects which amount to more than the sum of their parts.
What there isn’t, however, is supplementary guidance for research and development investment. In January 2024, former science minister David Willetts reviewed DSIT’s business case and approvals process, and one of his recommendations was for such guidance to be created:
“The Green Book treats technology as an exogenous and unpredictable source of risk. It never appears as something which we have any capacity to invest in and shape as a source of economic benefit and better public services.”
Willetts also suggested that, for science and technology investment, the Green Book method was being “trumped” by security concerns – Whitehall couldn’t conceptualise the benefits of R&D sufficiently well to invest in it itself, but equally did not want it to be funded by investors from elsewhere in the world.
His central conclusion was that the value and appraisal of spending on science, innovation and technology are “intermittently understood but not reflected in the key documents governing spending on R&D.” He called for the department to work with the Treasury to review how the Green Book treats R&D, and produce supplementary guidance.
DSIT’s response accepted Willetts’ recommendations in full – on the question of appraisals, the now defunct department said it would produce and roll out new guidance for R&D business cases internally, and longer term seek to agree a Green Book supplement.
Earlier this month we learned that in December 2025 DSIT commissioned an external report – from consultants SQW in partnership with the Innovation and Research Caucus among others – on how value for money assessment could be strengthened in business cases for R&D policies. It develops a suggested value for money framework which could be used across government for making “balanced judgements” about proposals involving R&D.
As the report sets out, there are various reasons why the Green Book’s current approach to assessing the value for money of a proposal fits somewhat awkwardly with R&D. The benefits of R&D can be hard to monetise, and the path to impact can be long and complex. Projects are likely to be highly front-loaded with costs, and there tends to be a substantial degree of risk and uncertainty, meaning that those drawing up business cases can find the prospects of a proposal hard to articulate. And the new emphasis in the Green Book on place – whereby it will be necessary to ensure that “all groups and places can engage in and benefit from R&D activities” – does not necessarily map neatly to something as diffuse as research and innovation.
The team behind the report proposes two additional criteria in making value for money assessments: the “strategic value” of a proposal, such as its alignment with national priorities, and its “robustness” to risk and uncertainty. Shortlisted courses of action would be assessed against the criteria (six in all) against a set of performance standards.
The authors recognise that there could be concerns about subjectivity in the framework they suggest, and that any process changes within government (especially those which are really culture changes) require work – there would be a need for “socialising” the new approach, as they put it.
But the report indicates that plans for a better approach to R&D business cases are moving forward, to some degree at least, and that David Willetts’ recommendations are not simply gathering dust, even if changing the complex Treasury processes for greenlighting investments is no small undertaking.
The publication is accompanied by a set of international case studies, which conclude that the UK is already leading the field in attempting to better make the case for R&D investments, and of the countries reviewed only Japan currently has R&D specific appraisal guidance in operation. What’s also clear is that around the world governments are recognising that the conventional approach is lacking when it comes to the “big bets” on science and innovation that many countries want to promote:
“While traditional cost-benefit analyses remain a cornerstone of policy, they are increasingly insufficient for capturing the ‘additionality’ and transformative impacts of modern, mission-oriented investments.”